Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl):11–16.
2. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427–434.
3. Gee MS, Procopio WN, Makonnen S, et al.: Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003, 162:183–193.
4. Badalian G, Derecskei K, Szendroi A, et al.: EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res 2007, 27:889–894.
5. Houk BE, Bello CL, Michaelson MD, et al.: Exposure-response of sunitinib in metastatic renal cell carcinoma: a population pharmacokinetic/pharmacodynamic approach [ASCO abstract]. J Clin Oncol 2007, 25:18S(Suppl):5027.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献